Psychotropic Agents

1. Front Matter

   Pages I-XXVI

   PDF

2. Psychotomimetics

   1. Front Matter

      Pages 1-1

      PDF

   2. Chemistry of Psychotomimetics

      • A. T. Shulgin

      Pages 3-29

   3. Pharmacology and Toxicology of Psychotomimetics

      • L. E. Hollister

      Pages 31-44

   4. Psychotomimetics: Behavioral Pharmacology

      • J. B. Appel, A. D. Poling, D. M. Kuhn

      Pages 45-55

   5. Biochemical Pharmacology of Psychotomimetics

      • D. X. Freedman, W. O. Boggan

      Pages 57-88

   6. Neurophysiologic Properties of Psychotomimetics

      • G. K. Aghajanian

      Pages 89-109

   7. Dependence-Producing Liability of LSD and Similar Psychotomimetics

      • A. D. Poling, J. B. Appel

      Pages 111-116

3. Cannabis

   1. Front Matter

      Pages 117-117

      PDF

   2. Chemistry of Cannabis

      • R. Mechoulam

      Pages 119-134

   3. Pharmacology and Toxicology of Cannabis

      • H. Coper

      Pages 135-158

4. Alcohol

   1. Front Matter

      Pages 159-159

      PDF

   2. General Pharmacology and Toxicology of Alcohol

      • T. L. Chruściel

      Pages 161-176

   3. Behavioral Pharmacology of Alcohol

      • N. K. Mello

      Pages 177-208

   4. Biochemical Pharmacology of Alcohol

      • J. Ellingboe, J. H. Mendelson

      Pages 209-237

   5. Dependence-Producing Effects and Alcohol Dependence Syndrome

      • T. L. Chruściel

      Pages 239-265

5. Psychotropic Effects of Central Acting Drugs

   1. Front Matter

      Pages 267-267

      PDF

   2. Psychotropic Effects of Opioids and Opioid Antagonists

      • S. R. Goldberg, R. D. Spealman, H. E. Shannon

      Pages 269-304

   3. Hypnotics

      • W. R. Martin

      Pages 305-329

   4. Anticholinergics

      • L. G. Abood

      Pages 331-347

The description of the pharmacology of psychotomimetics, cannabis, and alcohol in this third volume concludes the discussion on psychotropic agents. As psychomotor stimulants these groups of psychotropic agents are of little or no therapeutic relevance, but since they are used in a nonmedical manner, or are even considered by some groups of the population as social commodities, their behavioral effects and psychopharmacological properties are not the concern of the pharmacol­ ogist alone. The same is true of psychotomimetics, as well as cannabis and its components. Psychotomimetics have a social history going back many hundreds of years and are among the most potent psychotropic agents known to man. The closing description of psychopharmacology also deals with the psychotropic effects of a number of drugs not primarily considered to be psychotropic. Their psychotropic effects are either an inherent constituent of their therapeutic profile, as is the case with opiates, hypnotics, and caffeine, or they may occur indirectly as side effects or accompanying effects during therapy. This applies to p-adrenoreceptor antagonists and anticholinergics. The editors are also aware that a description of psychotropic agents would not have been complete without discussing the medical, ethical, and legal aspects of the development, clinical testing, and use of such drugs.

• Acetylcholin
• Aldehyde
• Alkohol
• Rauschgift
• Serotonin
• alcohol
• analgesics
• cannabinoid
• chemistry
• neurotransmitter
• pharmacodynamics
• pharmacokinetics
• pharmacology
• research
• toxicology

• Institut für Pharmakologie, Bayer AG, Wuppertal 1, Germany

  F. Hoffmeister

• Institut für Arzneimittel des Bundesgesundheitsamtes, Berlin 30, Germany

  G. Stille

Policies and ethics